tiprankstipranks
Precigen Regains Full Control of Technology Post Agreement Termination
Company Announcements

Precigen Regains Full Control of Technology Post Agreement Termination

Don't Miss our Black Friday Offers:

The latest update is out from Precigen ( (PGEN) ).

Precigen, Inc. has reclaimed all rights to its technology following the termination of its Amended and Restated License Agreement with Alaunos Therapeutics, Inc., effectively revoking any access Alaunos once had. This marks a significant shift in control over the licensed technology since the original agreement in 2018.

Learn more about PGEN stock on TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskPrecigen Reports Q3 2024 Financial Results
TheFlyPrecigen reports Q3 EPS (9c), consensus (8c)
Catie PowersPGEN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App